• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.610 -0.010 (-0.62%)
Streaming Delayed Price Updated: 11:53 AM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
August 19, 2025
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
August 18, 2025
 
Via Benzinga
These stocks are moving in today's pre-market session
August 18, 2025
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 18, 2025
 
Via Benzinga
Inhibikase Posts Wider Loss in Q2
August 14, 2025
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 30, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
June 27, 2025
 
Via Benzinga
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
May 14, 2025
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
April 14, 2025
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
March 27, 2025
New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Announces Expansion of Senior Leadership Team
February 24, 2025
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
February 18, 2025
From Inhibikase Therapeutics
Via GlobeNewswire
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
February 12, 2025
 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
January 30, 2025
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Wednesday?
January 29, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
November 14, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
November 08, 2024
 
Via Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
November 08, 2024
 
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
October 24, 2024
 
Via Benzinga
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
October 21, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
October 14, 2024
 
Via Benzinga
Dow Surges 350 Points; US Crude Oil Stocks Increase
October 09, 2024
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 09, 2024
 
Via Benzinga
Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August
October 09, 2024
 
Via Benzinga
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today
October 09, 2024
Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing. 
Via Benzinga
Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results
October 09, 2024
 
Via Benzinga
Topics Stocks
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
October 09, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024
August 14, 2024
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
August 14, 2024
Company to host conference call on August 15, 2024 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 07, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  249.92
+3.73 (1.51%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap